Synmosa Biopharma (ROCO:4114) COGS-to-Revenue : 0.56 (As of Mar. 2025)

View and export this data going back to 2003. Start your Free Trial

What is Synmosa Biopharma COGS-to-Revenue?

Synmosa Biopharma's Cost of Goods Sold for the three months ended in Mar. 2025 was NT$809 Mil. Its Revenue for the three months ended in Mar. 2025 was NT$1,448 Mil.

Synmosa Biopharma's COGS to Revenue for the three months ended in Mar. 2025 was 0.56.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Synmosa Biopharma's Gross Margin % for the three months ended in Mar. 2025 was 44.14%.

Synmosa Biopharma COGS-to-Revenue Historical Data

The historical data trend for Synmosa Biopharma's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synmosa Biopharma COGS-to-Revenue Chart

Synmosa Biopharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.63

0.60

0.58

0.59

0.57

Synmosa Biopharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
COGS-to-Revenue	Get a 7-Day Free Trial															0.56	0.57	0.57	0.57	0.56

Synmosa Biopharma COGS-to-Revenue Calculation

Synmosa Biopharma's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	3148.641	/	5549.549
	=	0.57

Synmosa Biopharma's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	808.519	/	1447.511
	=	0.56

Synmosa Biopharma (ROCO:4114) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Synmosa Biopharma's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	808.519 / 1447.511
	=	44.14 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Synmosa Biopharma COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Synmosa Biopharma's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Synmosa Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Synmosa Biopharma Corp (ROCO:4114) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 6, Gongye 1st Road, Hukou Township, Hsinchu County, Hsinchu, TWN

Website

https://www.synmosa.com.tw

Synmosa Biopharma Corp is engaged in the research and development, manufacturing, marketing, and distribution of pharmaceutical products, medical devices, cosmetics, animal drugs, chemical food additives, and beverages. It is also involved in manufacturing and sales, and environmental drugs wholesale (retail), as well as the import and export of related businesses. The company provides prescription, OTC medicines, and healthcare products under its Synmosa trademark. The reporting segments of the company are; the Generic Drugs segment which derives key revenue, and the Active Pharmaceutical Ingredients segment.

Synmosa Biopharma Headlines

No Headlines